ONCAlert | Upfront Therapy for mRCC
Videos  >  

Assessing the Role of 21-Gene Assays in Breast Cancer

John H. Ward, MD
Published Online:1:45 PM, Wed May 1, 2019


John H. Ward, MD, Margaret A. Amundsen Endowed Professor of Medicine, Huntsman Cancer Institute, University of Utah School of Medicine, discusses the role of 21-gene assays in selecting patients with breast cancer for adjuvant chemotherapy treatment.

Patients who have a low 21-gene recurrence score can be spared chemotherapy. It is predicted that 46% of women with breast cancer can forego chemotherapy, according to Ward.

The 21-gene assay is used to identify a group of patients with a good enough prognosis that they can be spared the expense, toxicity, and trauma of the otherwise recommended adjuvant chemotherapy, he says.
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.